Compare UFI & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UFI | PMN |
|---|---|---|
| Founded | 1969 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Textiles | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.4M | 84.1M |
| IPO Year | 1994 | 2022 |
| Metric | UFI | PMN |
|---|---|---|
| Price | $6.10 | $9.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $42.71 |
| AVG Volume (30 Days) | ★ 53.2K | 31.5K |
| Earning Date | 11-03-2026 | 11-11-2026 |
| Dividend Yield | ★ 27.18% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $531,303,000.00 | N/A |
| Revenue This Year | $4.12 | N/A |
| Revenue Next Year | $9.69 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.96 | $0.29 |
| 52 Week High | $8.47 | $27.40 |
| Indicator | UFI | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 31.48 | 32.85 |
| Support Level | $5.95 | $9.20 |
| Resistance Level | $6.79 | $15.37 |
| Average True Range (ATR) | 0.21 | 0.96 |
| MACD | -0.04 | -0.17 |
| Stochastic Oscillator | 1.33 | 15.34 |
Unifi Inc is a multi-national company. It manufactures and sells synthetic and recycled products made from polyester and nylon predominantly to other yarn manufacturers and knitters and weavers that produce fabric for apparel, hosiery, home furnishings, automotive, industrial, and other end-use markets. Polyester yarns include partially oriented yarn (POY), textured, solution and package dyed, twisted, beamed, and draw wound yarns, and each is available in virgin or recycled varieties. UNIFI offers specialized yarns, premium value-added (PVA) yarns, and commodity yarns. The company's reportable segments are; the Americas, Brazil, and Asia. Its maximum revenue is derived from the Americas.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.